New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:04 EDTBTXBioTime raises $6.4M in equity financing
BioTime announced that on May 1, the company received approximately $6.4M in equity financing. The funds were raised from current long-term investors in the company and will be used for funding product development, including this year's anticipated pivotal Renevia clinical trial, as well as other general operating expenses.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
09:26 EDTBTXBioTime clinical-grade hES cell lines to be used in planned CIRM-funded study
BioTime announced that the clinical-grade human Embryonic Stem, or hES, cell lines from BioTimeís wholly-owned subsidiary ES Cell International Pte, will be used by UC Irvine scientist Dr. Leslie Thompson to continue her promising research in the use of stem cells to treat Huntingtonís disease under a $5M grant from the California Institute for Regenerative Medicine, or CIRM. The CIRM grant will further support a collaboration between ESI and UC Davisís good-manufacturing-practice, or GMP, laboratory for the creation of the GMP grade cells needed in Dr. Thompsonís preclinical and potentially subsequent clinical studies. This collaboration is an example of BioTimeís strategy to leverage collaborations and potentially generate future revenues by placing its hES cells in a wide array of medical applications that BioTime could not otherwise address with its own resources. ESI provides its hES cells as both inexpensive research-grade cells through its ESI BIO division and as GMP-compliant clinical grade cells for translation into clinical applications, allowing researchers to conduct research with hES cells that can also be used in the clinic.
April 22, 2015
08:09 EDTBTXBioTime announces nonexclusive license agreement with BRICOH
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use